Should minors be allowed access to gender-affirming medical treatments with parental consent?

Background

Gender-affirming care for minors refers to a range of medical interventions — including puberty blockers, hormone therapy, and in rare cases surgery — designed to help young people whose gender identity differs from their sex assigned at birth. According to the Williams Institute at UCLA, an estimated 300,100 youth between ages 13 and 17 identify as transgender in the United States, though available data suggest the number actually receiving medical treatment is small. This issue has become one of the most contested areas of health policy in recent years. According to KFF's policy tracker, 27 states have now enacted laws restricting or banning these treatments for minors, beginning with Arkansas in 2021. In June 2025, the U.S. Supreme Court ruled in United States v. Skrmetti that Tennessee's ban did not violate the Fourteenth Amendment's Equal Protection Clause, upholding states' authority to restrict such care. At the same time, according to the Movement Advancement Project, 17 states and Washington, D.C. have enacted shield laws protecting access, creating a sharp geographic divide. The Trump administration has also pursued federal actions to limit care, including proposed rules that would bar Medicaid and CHIP reimbursement for these treatments.

Supporters of allowing access with parental consent point to guidelines from major medical organizations — including the American Academy of Pediatrics, the Endocrine Society, and the American Medical Association — which describe gender-affirming care as evidence-based and medically necessary for appropriately evaluated patients. Research published in peer-reviewed journals, including studies cited by the National Institutes of Health, has found associations between gender-affirming treatment and reduced depression and suicidal ideation among transgender youth. Opponents raise concerns about the quality of the evidence base, pointing to the 2024 Cass Review commissioned by England's National Health Service, which found that evidence supporting these treatments was of low certainty and called for greater caution. A 2025 HHS report reached similar conclusions. Critics also argue that minors may lack the maturity to consent to treatments with potentially irreversible effects, and they note that some European countries have moved to restrict these interventions. The evidence debate itself remains actively contested, with researchers on both sides challenging each other's methodology and conclusions.

The stakes for affected families are significant. In states with bans, medical providers face professional sanctions or criminal penalties, and as reported by AAMC, some parents risk losing custody. According to NPR, even in states without bans, some hospitals have voluntarily stopped providing these services under pressure from the federal government. Gallup polling has found that more than six in ten Americans oppose laws banning gender-affirming care for minors, though views divide sharply along partisan lines. How this debate is resolved will shape whether medical decisions for transgender youth remain with families and physicians or are determined by state and federal policy — with real consequences for the health and well-being of a small but vulnerable population of young Americans.